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Hydroxypyridinones with enhanced iron chelating
properties. Synthesis, characterization and in vivo
tests of 5-hydroxy-2-(hydroxymethyl)pyridine-
4(1H)-one†
J. I. Lachowicz,*a V. M. Nurchi,a G. Crisponi,a M. G. Jaraquemada-Pelaez,a M. Arca,a
A. Pintus,a M. A. Santos,b C. Quintanova,b L. Gano,c Z. Szewczuk,d M. A. Zoroddu,e
M. Peana,e A. Domínguez-Martínf and D. Choquesillo-Lazarteg
The synthesis of 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (P1) is presented, together with the
evaluation of its coordination ability towards Fe3+, studied by a combination of chemical, computational,
and animal approaches. The use of complementary analytical techniques has allowed us to give evidence
of the tautomeric changes of P1 as a function of pH, and to determine their inﬂuence on the coordinating
ability of P1 towards Fe3+. The pFe3+ value 22.0 of P1–iron complexes is noticeably higher than that of
deferiprone (20.6), one of the three clinical chelating agents in therapeutic use for iron overload diseases.
This is due on one side to the tautomeric change to the catechol form, and on the other to the lower
protonation constant of the OH group. Bio-distribution studies on mice allowed us to conﬁrm in vivo the
eﬃcacy of P1. Furthermore the coordinating ability toward Al3+, Cu2+ and Zn2+ has been studied to evalu-
ate the possible use of P1 against a second toxic metal ion (Al3+), and to envisage its potential inﬂuence
on the homeostatic equilibria of essential metal ions. The chelating ability of P1 toward these ions, not
higher than that of the corresponding deferiprone, contributes to render P1 a more selective iron
chelator.
Introduction
Hydroxypyridinone ligands have been extensively studied as
candidates for orally active iron chelators since the 1980s. The
European Union approved 3-hydroxy-1,2-dimethylpyridin-
4(1H)-one (deferiprone, DFP) (Scheme 1) as a clinical chelating
agent for iron overload diseases in 2000. A major drawback of
DFP is that it undergoes extensive metabolism in the liver.
3-Hydroxy functionality, crucial for iron scavenging, is the
prime target of this metabolism. Urinary recovery studies in
rats and humans showed that >44% and >85% of the adminis-
tered dose is recovered as the non-chelating 3-O-glucuronide
conjugate respectively.1 This extensive biotransformation
limits the ability of DFP to mobilize the excess of iron in tha-
lassemic patients. Hydroxypyridinones share common features
with catechols and hydroxamic acids.2,3 The zwitterionic aro-
matic resonance form of deprotonated hydroxypyridinones is
isoelectronic with the catecholate dianion.4 This family of
ligands, encompassing three subfamilies, 1-hydroxy-2(1H)-pyri-
dinone (1,2-hopo), 3-hydroxy-2(1H)-pyridinone (3,2-hopo) and
3-hydroxy-4(1H)-pyridinone (3,4-hopo) (Scheme 1), form five-
Scheme 1 Hydroxypyridinone ligands and their acronyms.
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member chelate rings in which the metal ion is bound by two
oxygen atoms.4
There are more than 4968 publications related to DFP in
the literature (SciFinder 21st December 2015). Diﬀerent DFP
derivatives have been synthesized and characterized, the
majority of which involve substitutions in positions 1 and 2
with aliphatic and aromatic groups aimed at improving the
chelating properties, changing the lipophilicity and the solubi-
lity, or gaining additional properties such as fluorescence.
1′-Hydroxyalkyl substituents in position 2 lead to a reduction
of protonation and iron complex formation constants, as com-
pared to those of simple alkyl-substituted hopos. This results
from the combined eﬀect of intramolecular hydrogen
bonding, between the 2-(1′-hydroxyl) group and the adjacent
3-hydroxyl function, and also the negative inductive eﬀect of
the 2-(1′-hydroxyl) group from the pyridinone ring, stabilizing
the ionized species. Although such an eﬀect reduces the
overall stability constants for Fe3+, it also reduces the proton
aﬃnity of the chelating functions. These changes result in an
increase in the corresponding pFe3+ values at pH 7.4. Conver-
sely, the introduction of a hydroxyl function in position 2 does
not induce similar eﬀects, and instead results in a decrease in
lipophilicity as compared to the simple alkyl derivatives.1 An
additional increment is also observed with 6-alkyl substi-
tution.1 Generally, N-alkylation of 3,4-hopos results in little
change in the aﬃnity for protons as well as for Fe3+.5,6 Surpris-
ingly, only a few derivatives with hydrogen in position 1 are
known; 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one, with
its tautomeric forms, has been studied by computational
methods, but not accompanied by experimental studies.7
Although diﬀerent authors have debated about the tautomeric
equilibrium of the free DFP ligand and its derivatives, no
tautomeric equilibria in the corresponding metal complexes
have been experimentally proven.
Tautomers are usually characterized by diﬀerent hydro-
phobicities, pK values and structures, and therefore diﬀerent
coordination abilities. In this respect, the influence of the
medium polarity may be highly significant since a biological
system involves either an aqueous medium (blood or plasma),
or an essentially non-protic medium such as a cell membrane
or even an enzymatic reaction centre.8 Based on these con-
cerns, we considered that metal coordination may be improved
in 3,4-hopo with a N–H group in position 1, and hence in this
work we present a study on the coordination ability of
5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (P1) (Scheme 1)
towards Fe3+ by combining computational, chemical, and bio-
logical approaches. The use of complementary analytical tech-
niques has allowed us to give evidence of the tautomeric
changes of P1 as a function of pH, and to determine all of
their possible forms and properties. The coordinating ability
of P1 towards Fe3+ together with bio-distribution studies on
mice to evaluate in vivo its eﬃcacy is also presented. Further-
more the coordinating ability toward Al3+, Cu2+ and Zn2+ has
been studied to evaluate the possible use of P1 against a second
toxic metal ion (Al3+), and to envisage its potential influence
on the homeostatic equilibria of essential metal ions.
Experimental section
Reagents
5-Hydroxy-2-hydroxymethyl-pyran-4-one (kojic acid, KA),
ammonia, benzyl chloride, NaOH, KOH, FeCl3, HCl solution,
and ethanol were purchased from Aldrich, KCl from Carlo
Erba (Milan, Italy), gallium citrate 67Ga from Mallinckrodt
Medical B.V and desferal from Biofutura Pharma. All the
reagents were used without any further purification. Carbon-
ate-free 0.1 M KOH solution was prepared as previously
reported.9 The metal ion standard solutions were prepared by
dissolving the required amount of chloride salts in pure
double distilled water and adding a stoichiometric amount of
HCl to prevent hydrolysis. Fe3+ solution was standardized by
spectrophotometric analysis of the Fe3+–desferal complex,
while Al3+, Cu2+ and Zn2+ solutions were standardized by EDTA
titration.
5-Benzyloxy-2-(hydroxymethyl)-4H-pyran-4-one
Sodium hydroxide aqueous solution 11 M (10 mL) was added
to 100 mL of a solution of KA (14.2 g, 100 mmol) in MeOH
and the mixture was heated under reflux. Benzyl chloride
(12.75 mL, 111 mmol) was added drop-wise, and the reaction
mixture was refluxed overnight. Once the reaction was com-
plete (checked by TLC; eluent: DCM/MeOH, 1 : 0.75), the
mixture was cooled to room temperature. The precipitate was
filtered and washed with an ethylic ether/petroleum ether
mixture to obtain a light brown solid (18.016 g, 77% yield);
m.p. 129–131 °C (lit. value 129–130 °C (ref. 10) and 132 °C (ref.
11)). 1H NMR (300 Hz, MeOD), δ (ppm): 8.01 (s, 1H, 6-HPy),
7.44–7.32 (m, 5H, HPh), 6.51 (s, 1H, 3-HPy), 5.02 (s, 2H, CH2–
Bz), 4.41 (s, 2H, CH2–OH).
5-Benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one
5-Benzyloxy-2-(hydroxymethyl)-4H-pyran-4-one (6.25 g,
26.91 mmol) was dissolved in methanol (25 mL) and then 25%
ammonia aqueous solution (57.5 mL) was added. The mixture
was refluxed in an oil bath for 7 h and the progress of the reac-
tion was monitored by TLC (eluent: DMC/MeOH 6 : 0.75
solvent mixture). The reaction mixture was concentrated in a
rotary evaporator to obtain a pale brown solid residue, which
was re-crystallized from ethanol/ethyl ether, leaving the pure
target compound as a beige coloured product (5.659 g, 90%
yield); m.p. 224 °C (lit. value 225–226 °C (ref. 10)). 1H NMR
(300 Hz, DMSO), δ (ppm): 11.3 (s, 1H, NH), 7.42–7.30 (m, 5H,
HPh), 6.11 (s, 1H, 6-HPy), 5.70 (s, 1H, 3-HPy), 5.00 (s, 2H, CH2–
Bz), 4.33 (s, 2H, CH2–OH).
5-Hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (P1)
5-Benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one (2.542 g,
10.99 mmol) was dissolved in methanol (200 mL) and 10% Pd/
C (0.258 g) was added. The suspension was stirred for 4 h
under a H2 atmosphere (2 bar). Afterwards the mixture was fil-
tered and the solvent evaporated. Final recrystallization from
EtOH/Et2O aﬀorded a pale brown coloured pure product
(1.065 g, 70% yield); m.p. 245–247 °C. 1H NMR (300 Hz,
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MeOD), δ (ppm): 7.48 (s, 1H, 6-HPy), 6.44 (1s, 1H, 3-H-Py), 4.55
(s, 2H, CH2–OH).
13C NMR (400 Hz, D2O), δ (ppm): 171.73
(CvO), 147.43 (C–OH), 145.65 (2-C-Py), 121.71 (6-C-Py), 111.09
(3-C-Py), 59.52 (CH2 OH). Elemental analysis (%) calculated for
C6H7NO3: C 51.07; H 5.00, N 9.92%; found: C 50.53, H 5.12,
N 9.65%.
Analysis of the synthesized ligand
Elemental data were obtained using a Fisons EA1108 CHNS/O.
NMR spectra were recorded on a Bruker Ascend™ 400 MHz
spectrometer. Chemical shifts (δ) were reported in ppm
from the internal reference 3-trimethylsilyl-propionic acid-d4
sodium salt (DSS). The melting points were measured on a
Leica Galen III hot stage apparatus and are uncorrected.
Crystal structure determination
Single crystals of P1 were grown by slow evaporation of a
methanol solution (30 mg in 3 mL at 50 °C). A yellowish crystal
of P1 was mounted on a glass fibre and used for data collec-
tion. Yellowish crystals were prepared under inert conditions
immersed in perfluoropolyether as a protecting oil for manipu-
lation. A suitable crystal was mounted on MiTeGen Micro-
mount, and this sample was used for data collection. Crystal
data were collected at 100(2) K, using a Bruker D8 Venture
diﬀractometer (Mo K(α) radiation λ = 0.71073 Å). The data were
processed with APEX2 12 and corrected for absorption using
SADABS (transmission factors: 0.7456–0.6959).13 The structure
was solved by direct methods, which revealed the position of
all non-hydrogen atoms.14 These atoms were refined on F2 by a
full-matrix least-squares procedure using anisotropic displace-
ment parameters. All hydrogen atoms were located in diﬀer-
ence Fourier maps and included as fixed contributions riding
on attached atoms with isotropic thermal displacement para-
meters 1.2 (C–H, N–H) or 1.5 (O–H) times those of the respect-
ive atom. The absolute structure for the compound was chosen
according to the Flack parameter.15 Criteria of a satisfactory
complete analysis were the ratios of “rms” shift to standard
deviation less than 0.001 and no significant features in final
diﬀerence maps. Atomic scattering factors were taken
from “International Tables for Crystallography”.16 Molecular
graphics were plotted using PLATON17 and Olex2 programs.18
A summary of the crystal data, experimental details and refine-
ment results are listed in Table S1.† Crystallographic data have
been deposited with the Cambridge Crystallographic Data
Centre, CCDC 1056172 for ligand P1.
Potentiometric–spectrophotometric measurements
Protonation and complex-formation equilibria were carried out
as previously described, at ionic strength KCl 0.1 M.19 The
working ligand concentration was 4.9 × 10−4 M. Complex for-
mation studies were performed at 1 : 1, 1 : 2, and 1 : 3 metal/
ligand molar ratios. Combined potentiometric–spectrophoto-
metric measurements were done in the 200–400 nm spectral
range for protonation equilibria and in the 400–800 nm range
for Fe3+ complexation, using 0.2 and 1 cm path lengths,
respectively. Complex formation equilibria with Al3+, Cu2+ and
Zn2+ were potentiometrically studied. Protonation and
complex formation data were analysed using
HyperQuad2013 20 and HypSpec21 programs.
ESI-MS analysis
All MS experiments were performed on a Bruker microTOF-Q
spectrometer (Bruker Daltonik, Bremen, Germany), equipped
with an Apollo II electrospray ionization source with an ion
funnel. The instrument parameters were: scan range m/z
250–2000, dry gas – nitrogen, temperature 200 °C, ion source
voltage 4500 V, collision energy 10 eV, analyte aqueous
solutions (70 μL). Solutions were introduced at a flow rate of
3 μL min−1. The Bruker microTOF-Q spectrometer was cali-
brated with the Tunemix™ mixture (Bruker Daltonik,
Germany) in the quadratic regression mode. The mass spectro-
meter operated in the positive ion mode. Each spectrum was
obtained with more than 100 individual scans. The overall
charge of the analysed ions was calculated on the basis of the
distance between isotopic peaks. The formulae of the com-
plexes were determined by application of the Compass Data
Analysis program (Bruker Daltonik, Germany).22 The water and
D2O solutions of the ligand (1 × 10
−4 M) with FeCl3 and AlCl3
salts (1 : 3 metal to ligand molar ratio) and CuCl2, ZnCl2
(1 : 2 metal to ligand molar ratio) were incubated for 15 days at
room temperature before the measurements. Solutions at vari-
able pH and pD values were obtained by adding triethylamine
and HCl (water solution), or NaOD and DCl (D2O solutions).
pH and pD were measured on a previously calibrated pH-
meter.
NMR spectroscopy
NMR experiments were performed on a Bruker Ascend™
400 MHz spectrometer equipped with a 5 mm automated
tuning and matching broad band probe (BBFO) with z-gradi-
ents as previously reported.23 In particular, all the NMR experi-
ments were carried out with a ligand concentration of 5 mM in
D2O and H2O–D2O (90%–10%) solutions at 25 °C in 5 mm
NMR tubes. The solution pH, corrected for the deuterium iso-
topic eﬀect, was adjusted with diluted DCl and NaOD on a pH
meter Crison micro TT 2050 with an electrode Mettler Toledo
InLab 422. The concentration of Fe3+ and Ga3+ ions was
achieved by using a stock of acidic deuterated aqueous solu-
tion of FeCl3 and GaCl3 salts. The metal ions were added to P1
ligand solutions and the pH was then set to the right value
just before the acquisition of the spectra. 2-D 1H–13C HSQC
(heteronuclear single quantum coherence) spectra were
acquired by using a phase-sensitive sequence employing Echo-
Antiecho-TPPI gradient selection with a heteronuclear coup-
ling constant JXH = 145 Hz, and shaped pulses for all 180°
pulses on the f2 channel with decoupling during acquisition;
sensitivity improvement and gradients in back-inept were also
used.24–26 Relaxation delays of 2 s and 90° pulses of about
10 μs were applied in all the experiments. Solvent suppression
for 1D 1H, 2D 1H–1H TOCSY (total correlation spectroscopy)
and 1H–1H ROESY (rotating-frame Overhauser eﬀect spectro-
scopy) experiments were achieved by using excitation sculpting
Dalton Transactions Paper
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with gradients. The spin-lock mixing time of TOCSY experi-
ment was obtained with MLEV17.27 1H–1H TOCSYs were per-
formed by using mixing times of 60 ms. A combination of 1D,
2D TOCSY, HSQC and ROESY experiments was employed to
assign the signals of both free and metal-bound ligands at
diﬀerent pH values as previously reported for similar
systems.23,28–33 All NMR data were processed by using TopSpin
(Bruker Instruments) software and analysed by Sparky 3.11 34
and MestRe Nova 6.0.2 (Mestrelab Research S.L.) programs.
DFT calculation
Theoretical calculations were performed at the Density Func-
tional Theory (DFT) level35 with the Gaussian 09 package of
programs (Rev. A.02)36 on an E4 workstation equipped with
four quad-core AMD Opteron 2.2 MHz processors and 16 GB
of RAM and running the 64 bit version of the Ubuntu 12.04
Linux operating system. Barone and Adamo’s mPW1PW hybrid
functional was adopted,37 along with the Schäfer, Horn, and
Ahlrichs double-ζ plus polarization all-electron basis sets38
(BS) for all atomic species. The geometry of the compounds
was optimized with tight SCF convergence criterion and fine
numerical “pruned” integration grids (75 radial shells and 302
angular points per shell). The nature of the minima of each
optimized structure was verified by harmonic frequency calcu-
lations. NBO charge distributions39 and Wiberg40 bond indices
were calculated at the optimized geometries. Solvation calcu-
lations were carried out in the gas phase and water, implicitly
taken into account by means of the polarisable continuum
model (PCM) in its integral equation formalism variant
(IEF-PCM).41 The programs Gaussview 5.0.8,42 and Molden
5.2.4 43 were used to investigate the charge distributions and
optimized geometries.
Partition coeﬃcients
P1 and DFP octanol/water partition coeﬃcients (log P) were
calculated as the logarithm of the ratio of their concentrations
at 25 °C measured in the n-octanol phase and in the aqueous
phase (Tris, pH = 7.4), using the well-established “shake flask”
method.10,11,44–46 Each compound was added to a premixed
suspension, containing 3 mL of n-octanol and 3 mL of the
aqueous phase, and stirred for 4 h. The species concentration
in the aqueous layer was evaluated by spectrophotometry with
a Perkin Elmer Lambda 35 spectrophotometer, using a
thermostated 1 cm path length cell, on the benzenoid bands
of the compounds (λ = 280–290 nm). The measurements were
done in triplicate and repeated three times.
Biodistribution studies
67Ga-citrate injection solution was prepared by dilution of the
commercial 67Ga citrate solution with saline to obtain a final
radioactive concentration of 5–10 MBq per 100 μL. Biodistribu-
tion studies were carried out in groups of 3 female Balb-C
mice, weighing ca. 20–22 g (randomly bred, Charles River,
from CRIFFA, France). Mice were intravenously injected with
100 μL (5–10 MBq) of 67Ga citrate via the tail vein immediately
followed by an intraperitoneal injection of 0.35 μmol of each
ligand (P1 and DFP as a control) in 100 μL saline. Animals
were maintained on normal diet ad libitum and were sacrificed
by cervical dislocation at 1 h and 24 h post-administration.
The administered radioactive dose and the radioactivity in
sacrificed animals were measured in a dose calibrator (Aloka,
Curiemeter IGC-3, Aloka, Tokyo, Japan). The diﬀerence
between the radioactivities in the injected and in the sacrificed
animal was assumed due to the whole body excretion. Tissue
samples of main organs were then removed for counting in a
gamma counter (Berthold LB2111, Berthold Technologies,
Germany). Radioactivity remaining in the carcass was
measured in the dose calibrator and expressed as a percent of
injected activity (% I.A.). Biodistribution results were expressed
as a percent of injected activity per gram of organ (% I.A.
per g) and presented as mean values ± SD.
Results and discussion
Synthesis of P1
5-Hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one was synthesised
from kojic acid, following a standard synthetic procedure, pre-
viously described for the preparation of other pyridinones.44
The first step involves the protection of the 5-hydroxyl group of
KA with a benzyl group, by reaction with benzyl chloride and
formation of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one.
This was converted into the corresponding pyridinone,
5-benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one, by reaction
with an ammonia aqueous solution under reflux (Michael
addition, ring opening/closure, and dehydration). The benzyl
protecting group was then removed by catalytic hydrogenolysis
providing the final product P1 (Scheme 2).
Crystal structure of P1
The bond lengths and angles in the molecule P1 (Fig. 1) have
commonly encountered values (Table S3†). The substituents at
C4 and C5 are almost coplanar with the aromatic ring. In con-
trast, the torsion angle N1–C2–C7–O8 [−31.0(2)°] reveals a
noticeable twisting for the C2 hydroxymethyl group towards
the aromatic ring plane.
The crystal packing of P1 features infinite one-dimensional
zig-zag chains along the c axis, built up by classical hydrogen
bonding interactions: N1–H1A⋯O4c and O5–H5A⋯O8a (oper-
ators for generating equivalent atoms: a, −x + 1/2, −y + 1,
z − 1/2; c, −x + 1/2, −y + 1, z + 1/2, with R22 hydrogen-bonding
patterns (Fig. 2B).47
Each molecule forms an additional hydrogen bond
O8–H8A⋯O4b (b, −x + 1, y + 1/2, − z + 1/2) with a molecule of
a neighbouring chain to give an infinite three-dimensional
Scheme 2 Synthesis of P1.
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network (Fig. 2A). Hence, the O4-carbonyl atom acts twice as a
H-acceptor whereas the O8–H8A alcoholic moiety plays the
roles of both a H-donor and a H-acceptor. The structural com-
parison of P1 with kojic acid,48 shows that the O-heterocyclic
atom of kojic acid does not act as a H-acceptor in its crystal. In
clear contrast, the isolobal N1–H1A group of P1 (replacing the
O-heterocyclic donor of the kojic acid) acts as an H-donor for
intermolecular interactions. In addition, the torsion angle O1–
C2–C7–O8 [–167.8(2)°] in KA shows that the hydroxymethyl
substituent is oriented in the opposite direction with respect
to KA. These data will be of importance in the following con-
siderations of tautomeric forms.
Protonation equilibria
The protonation equilibria of P1 have been examined with
diﬀerent techniques. Potentiometric–spectrophotometric
measurements gave evidence of three diﬀerent deprotonation
steps according to the sequence (1).
H3Lþ ¼ H2L ¼ HL ¼ L2 ð1Þ
The loss of each proton markedly aﬀects UV absorption
spectra (Fig. S2A and B†), and three diﬀerent pH regions
(3–4.6, 7.3–10.5, and 10.6–13.2) relative to each single equili-
brium can be identified, characterized by diﬀerent bands and
well defined isosbestic points. These features allowed the
evaluation of the protonation constants (Table 1); the related
speciation plot is presented in Fig. 3A with the superimposed
heights of UV bands, obtained by spectral decomposition. The
trend of 1H NMR signals of protons H3, H6 and H7 vs. pH
(Fig. 3B, S4 and Table S27†) confirms the deprotonation
sequence (1).
The first deprotonation (pH 2–5) mainly aﬀects proton H3,
suggesting that the proton is lost from the protonated oxygen
in position 4. The signal of H6 reflects this eﬀect though to a
minor extent. The second step (pH 7.3–10.5), related to the
deprotonation of the 5-hydroxy group, mainly reflects on the
H6 chemical shift. The last deprotonation (pH > 10.6) aﬀects
predominantly the H7 signals of the methylene group, which
could be implied in a hydrogen bond between the OH group
and the now deprotonated nitrogen atom. The high pK of this
last dissociation suggests a keto–enol tautomer transition with
dissociation from the hydroxyl group.
The log K 9.00 and 3.37 are almost equal to those of 3,4-
hopo,4 and somewhat lower than those of DFP (Table 1).49
Conversely, the loss of a third proton is a new feature, which
implies an equilibrium with a catechol-like molecule that loses
its proton at basic pH values (log K 12.16). The deprotonation
at the ring NH group of DL-α-amino-β-(6-oxo-1,6-dihydro-
pyridin-6yl)propanoic acid (Stunzi et al.)50 is characterized by a
log K value of 11.8, similar to that of 2-hydroxypyridine
(11.7).51
The ESI-MS measurements in D2O give evidence of the
exchange of four labile protons with deuterium. The spectrum
of the ligand in the D2O solution (Fig. S9†) shows five signals
of diﬀerent intensities. The most intense signals at 145.070
m/z and 146.076 m/z correspond to [C6H5D3O3N]
+ and
[C6H4D4O3N]
+ deuterated on two or three oxygen atoms and on
a single nitrogen atom. The less intense signals at 142.050,
143.057 and 144.063 m/z match with the simulated spectra of
[C6H8O3N]
+, [C6H7DO3N]
+ and [C6H6D2O3N]
+. The ESI-MS
Fig. 1 Ball and stick structure and atom labelling scheme of P1.
Fig. 2 Crystal packing of P1 seen along the a (A) and b (B) directions.
Table 1 Protonation constants for P1 at 25 °C, 0.1 M KCl ionic strength,
obtained using the HyperQuad2013 program.20 Standard deviations are
given in brackets. The literature values for DFP (Scheme 1, HL’ in the
neutral form) and 3,4-hopo are reported for comparison
Species
P1
log K Species
DFP log K
(ref. 49)
3,4-Hopo log K
(ref. 4)
H3L
+ 3.37(7) H2L′
+ 3.66(1) 3.34(1)
H2L 9.00(1) HL′ 9.82(2) 9.01(1)
HL– 12.16(1) — —
Fig. 3 (A) Normalized heights of the peaks at 248 nm (blue), 273 nm
(red) and 307 nm (violet), obtained by spectral decomposition, super-
imposed on the speciation plot of the ligand. (B) Normalized chemical
shifts of H6 (●), H3 (□) and H7 (△) proton, superimposed on the specia-
tion plot of the ligand.
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signals of the free ligand at diﬀerent pH values (1.68, 6.13,
11.5 and 13.7, Table S28†) show that the molecular weight of
the ligand does not change during the first (140.032 m/z) and
third (139.032 m/z) deprotonation in the negative mode spec-
trum, and does not present positively charged signals at basic
pH. The presence of a peak at 139.032 m/z, a striking
peculiarity observed in aqueous solutions at pH > 11.5,
further confirms the last deprotonation process shown in
sequence (1).
The deprotonation sequence of P1 has been also investi-
gated at the DFT level by calculating the electronic energies of
the possibly protonated forms of the ligand at their ground
state optimized geometry. Based on the results recently pub-
lished on related systems, DFT calculations were performed by
using the mPW1PW hybrid functional37 and Schäfer, Horn,
and Ahlrichs double-ζ plus polarization all-electron basis sets
(BS) for all of the atomic species.38 In particular, the fully pro-
tonated cationic ligand H3L
+, the three possible isomers of the
neutral and monoanionic forms (H2L and HL
−, respectively),
and the completely deprotonated dianion L2− were optimized,
both in the gas phase and in water, implicitly taken into
account by using the integral equation formalism of the polar-
izable continuum model (IEF-PCM) within the self-consistent
reaction field (SCRF) approach (Scheme 3).41
A comparison of the metric parameters optimized for the
neutral isomer H2La in the gas phase with the corresponding
structural data (see above) shows very good agreement between
the two sets of data, the principal bond distances being varied
by less than 0.05 Å (Table S7†). No significant changes in the
optimized structural parameters were observed upon consider-
ing implicit solvation in the calculations; all the bond lengths
and angles diﬀer by less than 0.01 Å and 2°, respectively, for
all of the eight forms of the ligand considered here. All of the
compounds show a completely planar structure, except the
hydroxymethyl substituent, whose orientation depends on the
protonation pattern of the ligand. In particular, in the species
where N1 is deprotonated (H2Lb, HLa
−, HLc
−, and L2−), the
O8–H8 hydroxyl group is coplanar with the heterocyclic ring,
and H8 is oriented towards N1 (C2–C7–O8–H8 dihedral angle
∼0.0°), so that a hydrogen bond interaction can be observed
between the two atoms (N1⋯H8 distance in the range
1.663–1.907 Å; Fig. S1† for H2Lb). A Second-Order Perturbation
Theory Analysis (SOPTA) of the Fock matrix in NBO basis
allows for evaluation of the energy ESOPTA of the interaction
between the lone pair (LP) localized on N1 and the unfilled
natural orbitals of the O8–H8 hydroxyl group in the range
between 10.3 and 35.0 kcal mol−1 depending on the species.
On the other hand, in the forms of the ligand showing N1 pro-
tonated (namely H2La, H2Lc, and HLb
−), in agreement with
what was found experimentally for H2La, the O8–H8 moiety
lies outside the plane described by the rest of the molecule,
the N1–C2–C7–O8 and C2–C7–O8–H8 dihedral angles being in
the range of −23.0/–40.8 and −49.2/–78.8°, respectively
(Table S7 and Fig. S1† for H2La and H2Lc). Finally, in H3L
+,
although the C7 hydroxyl group is coplanar with the hetero-
cyclic ring, H8 is oriented opposite to N1 (C2–C7–O8–H8 di-
hedral angle ∼180.0°). An analysis of the total electronic
energies calculated for the three possible neutral tautomeric
forms of the ligand suggests the tautomer H2La to be the most
stable (H2Lb and H2Lc being less stable by about 7 and 5
kcal mol−1, respectively). This agrees with a first deprotonation
of the ligand concerning H4, as hypothesized based on
spectroscopic evidence, and with the X-ray diﬀraction analysis
discussed above. In agreement with experimental data, H2La is
stabilized by a hydrogen bond (O4⋯H5 distance = 1.885 Å;
Fig. S1†), the interactions between the LP localized on O4 and
the unfilled natural orbitals of the O5–H5 hydroxyl group
being calculated as ESOPTA = 10.6 kcal mol
−1.
As far as the monoanionic forms of the ligand are con-
cerned, the isomers HLa
− and HLc
− were calculated and found
to be more stable than HLb
− by 12 and 15 kcal mol−1, respecti-
vely, owing to the formation of two diﬀerent hydrogen bonds,
one involving the N1 atom and the hydroxymethyl pendant,
and the other the C4–O4 and C5–O5 groups (O5⋯H4 distance
in HLa
− = 1.684 Å; O4⋯H5 distance in HLc− = 1.775 Å; ESOPTA
∼27 and 18 kcal mol−1 for HLa− and HLc−, respectively). This
accounts for the mechanism suggested by experimental data
for the second deprotonation of the ligand, which should
involve the O5–H5 hydroxyl group, followed by a rearrange-
ment leading from the pyridinone HLb
− to the catechol-like
tautomer HLa
−.
Each technique has given evidence of tautomeric forms,
and together they provided a complete description of the
deprotonation paths. As long as third deprotonation was not
observed for 3,4-hopo, we believe that –CH2OH in the position
2 is important for the tautomer change of the molecule.
Iron complexes
The iron complex formation was studied by potentiometric–
spectrophotometric combined titrations, ESI-MS and NMR.
Some spectra collected during a Fe3+–P1 titration are presented
in Fig. 4, representative of the transformations that occur with
pH. Up to pH 2 a new band centred at 550 nm increases in
Scheme 3 Lewis structures of the diﬀerently protonated forms of P1
optimized at the DFT level.
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intensity (Fig. 4A), due to the formation of a [FeLH]2+ complex
from the colourless hexaaquo-iron species. In the pH range of
2–3 (Fig. 4B) a new band appears at 500 nm with a clear iso-
sbestic point at 585 nm, related to the formation of a [FeL2H2]
+
complex. By increasing the pH a new band forms at 460 nm
related to the neutral [FeL3H3] complex, with an isosbestic
point at 488 nm. The behaviour up to pH 5 is similar to that of
deferiprone that presents in sequence similar bands due to
the formation of 1 : 1, 1 : 2 and 1 : 3 complexes.49 A diﬀerent
behaviour is featured by P1 at pH > 5: first a new band appears
at 445 nm with a clear isosbestic point at 464 nm, that at pH >
9 further transforms into a new band at a slightly higher wave-
length, with an isosbestic point at 485 nm. These last trans-
formations, taking into account the potentiometric results, are
related to the loss of a proton from the neutral species mod-
elled as FeL3H3 (possibly corresponding to Fe(HL)3) giving a
negatively charged complex modelled as [FeL3H2]
−, and then
of two further protons to give the [FeL3]
3− complex. Such
changes were observed above pH 7 by Scarrow et al. for 3,2-
hopo, but not for 3,4-hopo.4 The first isosbestic point of the
tris(3,2-hopo) iron complex at 494 nm was attributed by the
authors to the mono-deprotonation with a pK value of 9.04.
A second deprotonation occurred around pH 11. It has to be
remarked that, while DFP and P1 iron complexes exhibit good
solubility in the pH range of 2–11, the neutral tris(hydroxy-
pyridinonato) iron complexes with the three hopo ligands
studied by Scarrow et al.4 are quite insoluble. The
negative charge in the complexes of P1 with a general model
[FeL3H3–n]
n− further contributes to increase their solubility.
The stability constants of the Fe3+–P1 complexes obtained
by the spectrophotometric–potentiometric results are reported
in Table 2, and the related speciation plot in Fig. 5.
The pFe3+ value 22.0 of P1–iron complexes is noticeably
higher than that of deferiprone (20.6),49 3,4-hopo (20.6)4 and
3,2-hopo (16.3).4 This is due on one side to the loss of the
nitrogen proton from the complex with model FeL3H3, with
the corresponding tautomeric change to the catechol form,
and on the other to the protonation constant of the OH group
lower in P1 than in deferiprone.
The ESI-MS data confirm the potentiometric–spectrophoto-
metric results. Positively charged complexes form at acidic
Fig. 4 Spectra obtained by increasing the pH values of the Fe3+–P1
system (25 °C, 0.1 M KCl ionic strength, P1 concentration 4.9 × 10−4 M,
1 : 3 Fe/L molar ratio, optical path length 1 cm). These spectra were
divided in diﬀerent pH ranges to remark the transformations that are
occurring.
Table 2 Metal–ligand complex formation constants at 25 °C, 0.1 M KCl
ionic strength, obtained using the HyperQuad2013 program.20 Standard
deviations are given in brackets
Model
Fe3+ Al3+
Log β pK Log β pK
[MLH]2+ 25.92(9) 23.32(9)
[ML2H2]
+ 49.12(1) 45.18(6)
ML3H3 71.43(6) 65.25(7)
[ML3H2]
– 65.33(3) 6.1 58.30(4) 6.95
[ML3]
3– 46.03(5) 9.65 38.41(5) 9.95
pM 22.0 15.1
Model
Cu2+ Zn2+
Log β pK Log β pK
[MLH]+ 21.78(7) 18.79(6)
ML2H2 41.42(7) 36.70(4)
[ML2H]
– 34.21(5) 7.21 26.02(9) 10.68
[ML2]
2– 24.68(5) 9.53 —
pM 10.1 6.3
Fig. 5 Speciation plots of P1 complexes with Fe3+ at 1 µM metal ion
concentration and 10 µM ligand concentration (log β in Table 2).
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pH: [FeL2H2]
+ (336.004 m/z), [FeL2H2 + Cl
− + K+]+ (409.940 m/z)
and [FeL3H3 + K
+]+ (515.002 m/z), while at neutral and basic
pH [FeL2H2]
+ (336.004 m/z), [FeL3H3 + Na
+]+ (499.029 m/z) and
[FeL3H3 + K
+]+ (515.002 m/z), complexes are present. At basic
pH also, the formation of the negatively charged complex
[FeL2]
− (333.998 m/z) is observed (Fig. S10 and Table S29†).
The interaction of P1 with Fe3+ ions has been followed by
NMR at two diﬀerent pH values. In Fig. 6 the aromatic region
of the 1H NMR spectra of P1 is reported. The spectra were
obtained by using sub-stoichiometric amounts of Fe3+ ions,
from 0 : 1 up to 0.2 : 1 metal to ligand molar ratios at pH 7 and
11.5. Both aromatic protons, H3 and H6, are aﬀected by the
interaction with Fe3+ ions.
In the aromatic region of the 1H NMR spectra, at pH 7, a
selective broadening of signals was evidenced and both aro-
matic protons, H3 and H6, were aﬀected by the interaction
with Fe3+ ions. In particular, the H6 proton is the most
aﬀected suggesting the involvement in the coordination of the
deprotonated oxygen in the position 5 to give a FeL3H3
species.
Ga3+ ions have been used as a diamagnetic probe for the
paramagnetic Fe3+ ions, in order to prevent the NMR para-
magnetic line broadening. The aromatic region of the 1H NMR
spectra obtained by adding incremental amounts of Ga3+ ions
to P1 solution at neutral pH shows that, similarly to Fe3+, H6
and H3 were the most aﬀected protons by metal coordination,
giving however in this case an upfield and a downfield shift,
respectively (Fig. S7†).
The spectra obtained at pH 11.5 (Fig. 6) confirm that the
deprotonation of the pyridine nitrogen protons aﬀects, after
Fe3+ coordination, in the same way H3 as well as H6,
suggesting the deprotonation of both oxygen atoms at pH > 11
without any hydrolysis of the complex. These features are in
agreement with the proposed scheme of tautomerism.
For the Ga3+–P1 system, the signals H3 and H6 were
aﬀected, also at high pH, in a similar way to that of Fe3+–P1
(Fig. S8†).
Some of the authors recently used DFT calculations to
investigate the relative stabilities of Al3+ and Fe3+ complexes
featuring the 2,2′-[(2-hydroxy-3-methoxyphenyl)methanediyl]
bis [3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one] and 2,2′-[(4-
hydroxy-3-methoxyphenyl)methanediyl]bis[3-hydroxy-6-hydroxy-
methyl)-4H-pyran-4-one] ligands.52 Encouraged by these
results, we optimized the structures of the complexes Fe(HL)3
and [FeL3]
3− at the same level of theory as free ligands. In both
cases, the 3d5 Fe3+ metal ion has been considered to assume a
high-spin configuration (spin sextet state). In the neutral
complex, the metal ion is chelated by the three HL− ligands in
an only slightly distorted octahedral fashion (O4–Fe–O13 angle
= 96.15°; Fig. 7). The three ligand units show the corres-
ponding bond lengths and angles, with barely distinguishable
Fe–O (“hydroxy”) and Fe–O (“keto”) lengths in the complex
(Fe–O4 and Fe–O5 distances = 2.082 and 1.994 Å, respectively,
in the gas phase). A comparison of the metric parameters opti-
mized for Fe(HL)3 in the gas phase (Fig. 7 and Table S8†) with
the corresponding ones determined by X-ray diﬀraction for the
neutral complexes Fe(P2)3, isolated in Fe(P2)3·3H2O,
53 and
Fe(P3)3
54 show a very good agreement between the experimental
and calculated sets of data [P2 = 3-hydroxy-6-hydroxymethyl-
1-methylpyrid-4-onato; P3 = 1,2-dimethyl-3-hydroxypyrid-
4-onato]; average structural Fe–O distances: 2.007 and 2.018 Å;
C–O: 1.314 and 1.320 Å; O–Fe–O, 81.27° and 80.91 for Fe(P2)3
and Fe(P3)3, respectively; average calculated Fe–O distances:
2.039 Å; C–O: 1.275 Å; O–Fe–O, 79.29° for Fe(HL)3.
On passing from the gas phase to the optimization in water
carried out at the SCRF level, only minor variations in the
pattern of the bond lengths and angles were calculated
(average Fe–O bond distance: 2.036; C–O: 1.287 Å).
By complete deprotonation of the complex Fe(HL)3, the
anionic species [FeL3]
3− is ideally obtained. As expected, the
coordination environment at the high-spin central metal ion
is not changed as compared to the corresponding neutral
Fig. 6 Stacked aromatic region of 1D 1H NMR spectra of P1 by increas-
ing the sub-stoichiometric amounts of Fe3+, at pH 7 (left) and pH 11.5
(right) at 25 °C.
Fig. 7 Ball and stick drawing of the DFT-optimized molecular structure
of the neutral complex Fe(HL)3 (yellow = Fe; red = O; grey = C; blue = N;
white = H).
Paper Dalton Transactions
6524 | Dalton Trans., 2016, 45, 6517–6528 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
16
:5
1:
13
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
complex, with only a marginal elongation of the Fe–O and C–O
distances [average optimised Fe–O distances: 2.056 Å; C–O:
1.287 Å; O–Fe–O, 78.77°; corresponding average structural
metric parameters‡ for trianionic tris-catecholate Fe3+ com-
plexes: Fe–O, 2.01(3) Å; C–O, 1.33(2) Å; O–Fe–O, 80(1)°], reflect-
ing an unchanged pattern of bond orders at the iron centre
[average Wiberg40 bond index: 0.332 and 0.331 for FeL3H3 and
[Fe(L)3]
3−, respectively]. As observed for the free ligand, the
deprotonation of the N-heterocycles results in the formation of
hydrogen bonds between the nitrogen atoms and the hydroxy-
methyl pendants (distance N⋯H(O) = 1.724 Å). The SOPTA
allows evaluating the energy of the non-bonding hydrogen
interaction in 13.1 kcal mol−1 for each ligand in the gas phase.
This stabilization, amounting to about 40 kcal mol−1, might
be at the origin of the stability of such trianionic complexes.
Metal complexes
The complex formation equilibria of P1 with Al3+, Cu2+ and
Zn2+ have also been studied by potentiometric methods and
ESI-MS. The estimated complex formation constants are
reported in Table 2 and the speciation plots in Fig. 8.
We want to remark that the pAl3+, pCu2+, pZn2+ calculated
for P1 complexes are almost equal to those for deferiprone and
3,4-hopo (see Table S32†), in contrast with the net increase
relative to iron complexes. This behaviour drives us to define
P1 as an iron chelator more selective than deferiprone.
Lipophilicity and drug-like descriptors
Lipophilicity greatly influences the pharmacokinetic and phar-
macodynamic profile of a drug, and the partition coeﬃcient
between water and n-octanol (log P) is the parameter in use for
its evaluation. Log P of P1, and of DFP for comparison, were
measured with the “shake-flask” method. The obtained values
(Table 3) are quite similar, though that of P1 (−0.90) is slightly
less than that of DFP (−0.82). The same lipophilicity order was
obtained from in silico calculations, using the QikProp
program.55 This program provides also a number of indicators
of the pharmacokinetic profile of a drug, as the ability to cross
the blood–brain barrier (log BB), the ability to be absorbed
through the intestinal tract to the bloodstream (Caco-2 cell per-
meability) and the verification of Lipinski’s rule of five45
(Table 3).
Although P1 does not present any violation of the restricted
Lipinski’s rule, it presents some limitations to the barrier-
crossing ability compared to DFP. In particular, P1 presents
lower permeability through the Caco-2 membranes (higher
than 500 nm s−1 is considered good),55 as well as through the
blood–brain barrier (log BB < −1.0, poorly distributed to the
brain) and thus lower bioavailability into the central nervous
system. Interestingly the tautomeric diphenolic form H2Lb is
characterized by slightly better pharmacokinetic descriptors
than H2La, namely in terms of membrane permeability, due to
the increased aromaticity of the molecule that involves a lipo-
philicity enhancement.
Biodistribution studies
To evaluate the eﬃcacy of the new ligand P1 as a chelating
agent for mobilization of metal ions, we studied the biodistri-
bution profile of the well-established radiotracer 67Ga-citrate in
female mice with simultaneous intraperitoneal administration
of the ligand solution. The eﬀect of this chelator on the 67Ga
uptake and clearance on the major organs and on the
excretion can be viewed in comparison with the drug DFP
(Fig. 9).
Fig. 8 Speciation plots of P1 model complexes with (A) Al3+, (B) Cu2+
and (C) Zn2+ at 1 μM metal ion concentration and 10 µM ligand concen-
tration (log β in Table 2).
‡Average metric parameters calculated from a search on the Cambridge Crystal-
lographic Database (CSD 5.36 updated Nov. 2014) on entries with ref. code:
MOMLOR, BICSEL, CEZYIR, FUDRUR, FUDRUR10, GARWUR, GARWUR,
JUTVOJ, JUTWAW, JUTWEA, KCATFE, SUCCUO, SUCDAV, SUCDAV10, WEDDUF
(CQ 1.17 build RC5).
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 6517–6528 | 6525
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
16
:5
1:
13
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Although the eﬀect of DFP on the biodistribution of the
radiotracer in metal-overload mice has been previously
reported, those studies involved a diﬀerent animal model
(CD1)56,57 and so it was necessary to reevaluate it herein for
Balb-C mice.
The co-administration of the ligand P1 enhanced the
overall excretion rate of radioactivity from whole animal body
as eﬃciently as DFP, 24 and 48 h after administration. No sig-
nificant diﬀerences in the radioactivity remaining in the
carcass and in the rate of radioactivity elimination were found,
except at 1 h.
The main diﬀerences in the distribution profile are related
with the blood clearance and the hepatic uptake at 1 h. P1
induces slower clearance from blood as well as lower liver
uptake than DFP at 1 h after administration, which may be
attributed to the highest level of plasmatic protein binding,
eventually due to the 2-hydroxymethyl group and to some
minor decrease in the lipophilicity.
Overall, this biodistribution profile, similar to that of DFP,
shows an increase of the radiotracer elimination rate and
attests the ability of the ligand to chelate the radiometal
in vivo.
Conclusions
P1 combines the hydroxypyridinone and catechol features: at
low pH it coordinates eﬃciently with metal ions as 5-hydroxy-
2-(hydroxymethyl)pyridin-4(1H)-one, while at basic pH as
2-(hydroxymethyl)pyridine-3,4-diol. The presence of hydroxy-
methyl group favours the tautomeric equilibrium in the free
ligand, due to the formation of the hydrogen bond N1⋯H8.
The tautomeric transformation in the presence of metal ions
occurs at a lower pH than in the free ligand. On the basis of
pFe3+ values, P1 should be considered a more eﬃcient iron
chelator (pFe3+ 22.0) than the clinically-used DFP (20.67),49 its
3,4-hopo analogues (20.77) and far more eﬀective than cate-
chol (pFe 14.7).58 The high pFe3+ value of P1 depends on two
diﬀerent factors, namely (i) the high stability of the iron com-
plexes, mainly attributed to the tautomeric rearrangement of
the pyridinone ligand into the catechol-like ligand; and (ii) the
log K 9.00 of P1, lower than that determined for deferiprone by
0.82 units. The chelating ability of P1 toward aluminium,
copper and zinc ions is not higher than that of the corres-
ponding DFP and 3,4-hopo, and this renders P1 a more selec-
tive iron chelator.
The bio-distribution studies on mice showed that P1 is as
eﬀective as clinically-used DFP, notwithstanding the negative
charge on the complex existing at physiological pH (where the
species modelled as [FeL3H2]
− is prevalent) which could
hinder to some extent the crossing of membranes, and thus
iron excretion, suggesting that it is worthwhile to assess its
in vivo eﬃcacy after oral administration. The bioavailability
parameters presented in Table 3 characterize P1 as a less
eﬀective compound than DFP, even if the diﬀerence between
the parameters of H2La and H2Lb should mitigate this limit.
The study of metabolism of P1 in living organisms could be of
paramount importance, since it has been reported that
1′-hydroxyalkyl substituents prevent glucuronidation in vivo in
hydroxypyridinones.
These overall promising results urge further studies to
verify in vivo if the toxicity, bioavailability and pharmacokinetic
properties of P1 can open a new way to future clinical trials.
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Table 3 Experimental values of octanol/water coeﬃcient log P for P1
(in the neutral forms H2La and H2Lb) and DFP, and calculated values for
clog P, ability to cross the blood–brain barrier (log BB), ability to be
absorbed through the intestinal track to the blood (Caco-2 cell per-
meability), bioavailability into the central nervous system and the veriﬁ-
cation of Lipinski’s rule of ﬁve45
Name DFP H2La H2Lb
MW 138 141 141
log Pa −0.82 −0.90 —
clog Pb 0.915 −0.795 0.520
log BBb,c −0.254 −1.021 0.978
Caco-2 permeability (nm s−1)b 1141 192 256
CNSb +/− — —
Violations of Lipinski’s rulesb 0 0 0
aOctanol/water partition coeﬃcients, values measured in the present
work. b Predicted values using the program QikProp v.2.5.55 c Blood/
brain partition coeﬃcient.
Fig. 9 Biodistribution data in the most relevant organs, expressed as %
I.A. per g for 67Ga-citrate with simultaneous intraperitoneal injection of
P1 or deferiprone, at 1, 24 and 48 h after administration in female Balb-C
mice (n = 3).
Paper Dalton Transactions
6526 | Dalton Trans., 2016, 45, 6517–6528 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
16
:5
1:
13
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Notes and references
1 Z. D. Liu, H. H. Khodr, D. Y. Liu, S. L. Lu and R. C. Hider,
J. Med. Chem., 1999, 42, 4814–4823.
2 M. A. Santos, Coord. Chem. Rev., 2002, 228, 187–203.
3 M. A. Santos, S. M. Marques and S. Chaves, Coord. Chem.
Rev., 2012, 256, 240–259.
4 R. C. Scarrow, P. E. Riley, K. Abu-Dari, D. L. White and
K. N. Raymond, Inorg. Chem., 1985, 24, 954–967.
5 P. S. Dobbin, R. C. Hider, A. D. Hall, P. D. Taylor,
P. Sarpong, J. B. Porter, G. Xiao and D. van der Helm,
J. Med. Chem., 1993, 36, 2448–2458.
6 B. L. Rai, L. S. Dekhordi, H. Khodr, Y. Jin, Z. Liu and
R. C. Hider, J. Med. Chem., 1998, 41, 3347–3359.
7 I. Rogachevskii, V. Plakhova and T. Shelykh, Russ. J. Gen.
Chem., 2009, 79, 104–116.
8 A. R. Katritzky, C. D. Hall, B. El-Gendy and B. Draghici,
J. Comput.-Aided Mol. Des., 2010, 24, 475–484.
9 A. Albert and E. P. Serjeant, Ionization constants of acids and
bases: a laboratory manual, Methuen, 1962.
10 L. Saghaie, M. Pourfarzam, A. Fassihi and B. Sartippour,
Res. Pharm. Sci., 2013, 8, 233.
11 S. Fakih, M. Podinovskaia, X. Kong, H. L. Collins,
U. E. Schaible and R. C. Hider, J. Med. Chem., 2008, 51,
4539–4552.
12 APEX2, Software, V2014.11, Bruker AXS, Inc., Madison, Wis-
consin, USA, 2014.
13 SADABS, Program for Empirical Absorption Correction of Area
Detector Data, University of Goettingen, Germany, 2012.
14 G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystal-
logr., 2008, 64, 112–122.
15 S. Parsons and H. D. Flack, Acta Crystallogr., Sect. A: Found.
Crystallogr., 2004, 60, s61.
16 A. J. C. Wilson, International Tables for Crystallography,
Kluwer Academic Publishers, Dordrecht, The Netherlands,
1995.
17 A. L. Spek, Acta Crystallogr., Sect. D: Biol. Crystallogr., 2009,
65, 148–155.
18 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. Howard
and H. Puschmann, J. Appl. Crystallogr., 2009, 42, 339–
341.
19 V. M. Nurchi, G. Crisponi, J. I. Lachowicz, S. Murgia,
T. Pivetta, M. Remelli, A. Rescigno, J. Niclós-Gutíerrez,
J. M. González-Pérez and A. Domínguez-Martín, J. Inorg.
Biochem., 2010, 104, 560–569.
20 http://www.hyperquad.co.uk/HQ2013.htm, 07-05-2015.
21 P. Gans, A. Sabatini and A. Vacca, Ann. Chim., 1999, 89,
45–49.
22 Bruker, ESI Compass 1.3; DataAnalysis Version 4.0 (Build
234) Daltonik GmbH http://www.bdal.com.
23 M. A. Zoroddu, M. Peana and S. Medici, Dalton Trans.,
2007, 379–384.
24 A. G. Palmer, J. Cavanagh, P. E. Wright and M. Rance,
J. Magn. Reson., 1991, 93, 151–170.
25 L. Kay, P. Keifer and T. Saarinen, J. Am. Chem. Soc., 1992,
114, 10663–10665.
26 J. Schleucher, M. Schwendinger, M. Sattler, P. Schmidt,
O. Schedletzky, S. J. Glaser, O. W. Sørensen and
C. Griesinger, J. Biomol. NMR, 1994, 4, 301–306.
27 T. L. Hwang and A. Shaka, J. Magn. Reson., Ser. A, 1995,
112, 275–279.
28 M. A. Zoroddu, S. Medici, M. Peana and R. Anedda, Dalton
Trans., 2010, 39, 1282–1294.
29 S. Medici, M. Peana, L. G. Delogu and M. A. Zoroddu,
Dalton Trans., 2012, 41, 4378–4388.
30 M. Remelli, M. Peana, S. Medici, L. G. Delogu and
M. A. Zoroddu, Dalton Trans., 2013, 42, 5964–5974.
31 M. F. Peana, S. Medici, A. Ledda, V. M. Nurchi and
M. A. Zoroddu, Sci. World J., 2014, 2014.
32 V. M. Nurchi, G. Crisponi, M. Arca, M. Crespo-Alonso,
J. I. Lachowicz, M. A. Zoroddu, M. Peana, G. Pichiri,
M. A. Santos, S. M. Marques, J. Niclos-Gutierrez,
M. J. Gonzalez-Perez, A. Dominguez-Martin,
D. Choquesillo-Lazarte, Z. Szewczuk, D. Mansoori and
L. Toso, J. Inorg. Biochem., 2014, 141, 132–143.
33 M. Peana, S. Medici, V. M. Nurchi, J. I. Lachowicz,
G. Crisponi, M. Crespo-Alonso, M. A. Santos and
M. A. Zoroddu, J. Inorg. Biochem., 2015, 148, 69–77.
34 T. D. Goddard and D. G. Kneller, Sparky – NMR Assignment
and Integration Software, Version 3.11, University of Califor-
nia, San Francisco, CA, 2008.
35 W. Koch and M. C. Holthausen, A chemist’s guide to density
functional theory, Wiley-Vch, Weinheim, 2001.
36 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria,
M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone,
B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato,
X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng,
J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda,
J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao,
H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta,
F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers,
K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand,
K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar,
J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene,
J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo,
R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin,
R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin,
K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador,
J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas,
J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, Gaus-
sian 09, Rev. A.02, Gaussian, Inc., Wallingford CT, 2009.
37 C. Adamo and V. Barone, J. Chem. Phys., 1998, 108, 664–
675.
38 A. Schäfer, H. Horn and R. Ahlrichs, J. Chem. Phys., 1992,
97, 2571–2577.
39 A. E. Reed, R. B. Weinstock and F. Weinhold, J. Chem.
Phys., 1985, 83, 735–746.
40 K. B. Wiberg, Tetrahedron, 1968, 24, 1083–1096.
41 J. Tomasi, B. Mennucci and R. Cammi, Chem. Rev., 2005,
105, 2999–3094.
42 R. Dennington, T. Keith and J. Millam, GaussView, Version
5.0.8, Semichem Inc., Shawnee Mission, KS, 2009.
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 6517–6528 | 6527
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
16
:5
1:
13
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
43 G. Schaftenaar and J. H. Noordik, J. Comput. – Aided Mol.
Des., 2000, 14, 123–134.
44 R. Grazina, L. Gano, J. Šebestík and M. A. Santos, J. Inorg.
Biochem., 2009, 103, 262–273.
45 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney,
Adv. Drug Delivery Rev., 2012, 64, 4–17.
46 A. Leo, C. Hansch and D. Elkins, Chem. Rev., 1971, 71, 525–
616.
47 J. Bernstein, R. E. Davis, L. Shimoni and N. L. Chang,
Angew. Chem., Int. Ed., 1995, 34, 1555–1573.
48 J. Lokaj, J. Kožíšek, B. Koreň, M. Uher and V. Vrabel, Acta
Crystallogr., Sect. C: Cryst. Struct. Commun., 1991, 47, 193–
194.
49 V. M. Nurchi, G. Crisponi, T. Pivetta, M. Donatoni and
M. Remelli, J. Inorg. Biochem., 2008, 102, 684–692.
50 H. Stunzi, L. Harris, D. Perrin and T. Teitei, Aust. J. Chem.,
1980, 33, 2207–2220.
51 E. Spinner and J. White, J. Chem. Soc. B, 1966, 991–995.
52 V. M. Nurchi, J. I. Lachowicz, G. Crisponi, S. Murgia,
M. Arca, A. Pintus, P. Gans, J. Niclos-Gutierrez,
A. Domínguez-Martín, A. Castineiras, M. Remelli,
Z. Szewczuk and T. Lis, Dalton Trans., 2011, 40, 5984–
5998.
53 J. J. Molenda, M. A. Basinger, T. P. Hanusa and
M. M. Jones, J. Inorg. Biochem., 1994, 55, 131–146.
54 J. Charalambous, A. Dodd, M. McPartlin, S. O. Matondo,
N. D. Pathirana and H. R. Powell, Polyhedron, 1988, 7,
2235–2237.
55 QikProp, Version 2.5, LCC, New York, NY, 2005.
56 S. Chaves, A. Capelo, L. Areias, S. M. Marques, L. Gano,
M. A. Esteves and M. A. Santos, Dalton Trans., 2013, 42,
6033–6045.
57 L. Toso, G. Crisponi, V. M. Nurchi, M. Crespo-Alonso,
J. I. Lachowicz, D. Mansoori, M. Arca, M. A. Santos,
S. M. Marques, L. Gano, J. Niclós-Gutíerrez, J. M. González-
Pérez, A. Domínguez-Martín, D. Choquesillo-Lazarte and
Z. Szewczuk, J. Inorg. Biochem., 2014, 130, 112–
121.
58 V. M. Nurchi, T. Pivetta, J. I. Lachowicz and G. Crisponi,
J. Inorg. Biochem., 2009, 103, 227–236.
Paper Dalton Transactions
6528 | Dalton Trans., 2016, 45, 6517–6528 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
16
:5
1:
13
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
